Latest Content

Explore the evolving language of mental health as it intersects with societal issues, highlighting the importance of the term "upstander" in psychiatry.

Explore the intersection of cultural trauma and mental health, emphasizing the importance of awareness and education in preventing future conflicts.

A clinical trial reveals challenges in assessing schizophrenia symptoms due to cultural and language differences, highlighting the need for improved measurement tools.

Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

Explore the complex relationship between epilepsy and psychosis, including forced normalization and treatment strategies for affected patients.

Athletes navigate stress as a performance factor, learning to harness it for optimal results through effective management strategies and support systems.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.

Psychiatry is the medical specialty that wrestles with the included middle—requiring judgment, patience, and humility.